Circulating tumour DNA sequencing reveal mechanisms of resistance to BRAF-targeted therapies in BRAF-mutated gastrointestinal stromal tumour

Eur J Cancer. 2023 Jan:179:25-27. doi: 10.1016/j.ejca.2022.10.018. Epub 2022 Nov 1.

Authors

Mariella Spalato Ceruso¹, Maud Toulmonde¹, Laura Blouin², Antoine Italiano³

Affiliations

¹ Early Phase Trials Unit, Institut Bergonié, Bordeaux, France.
² Department of Pathology, Institut Bergonié, Bordeaux, France.
³ Early Phase Trials Unit, Institut Bergonié, Bordeaux, France; DITEP, Gustave Roussy, Villejuif, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr.

PMID: 36470024
DOI: 10.1016/j.ejca.2022.10.018

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Circulating Tumor DNA* / genetics
Gastrointestinal Stromal Tumors* / drug therapy
Gastrointestinal Stromal Tumors* / genetics
Gastrointestinal Stromal Tumors* / pathology
Humans
Melanoma* / genetics
Mutation
Proto-Oncogene Proteins B-raf / genetics

Substances

Proto-Oncogene Proteins B-raf
Circulating Tumor DNA
BRAF protein, human